Boston Scientific (BSX) Is Down 5.8% After EP Litigation Shadows FARAPULSE Trial Data Release - What's Changed

Simply Wall St.05-04

In late April 2026, Boston Scientific reported strong first-quarter results alongside reduced 2026 guidance, while unveiling extensive clinical data from Heart Rhythm 2026 supporting its FARAPULSE ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632322779?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","is_english":true,"pubTime":"2026-05-04 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632322779","market":"us","top_or_hot":-1,"title":"Boston Scientific (BSX) Is Down 5.8% After EP Litigation Shadows FARAPULSE Trial Data Release - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>In late April 2026, Boston Scientific reported strong first-quarter results alongside reduced 2026 guidance, while unveiling extensive clinical data from Heart Rhythm 2026 supporting its FARAPULSE ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-is-down-58-after-ep-litigation-shadows\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific (BSX) Is Down 5.8% After EP Litigation Shadows FARAPULSE Trial Data Release - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific (BSX) Is Down 5.8% After EP Litigation Shadows FARAPULSE Trial Data Release - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-04 18:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-is-down-58-after-ep-litigation-shadows><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late April 2026, Boston Scientific reported strong first-quarter results alongside reduced 2026 guidance, while unveiling extensive clinical data from Heart Rhythm 2026 supporting its FARAPULSE ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-is-down-58-after-ep-litigation-shadows\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4504","symbol_name":"桥水持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-is-down-58-after-ep-litigation-shadows","article_id":"2632322779","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-is-down-58-after-ep-litigation-shadows","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632322779","pubTimestamp":1777889953,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late April 2026, Boston Scientific reported strong first-quarter results alongside reduced 2026 guidance, while unveiling extensive clinical data from Heart Rhythm 2026 supporting its FARAPULSE pulsed field ablation platform, WATCHMAN left atrial appendage closure devices, and EMBLEM MRI subcutaneous defibrillator.\nAt the same time, multiple securities class actions were filed alleging misleading disclosures about electrophysiology growth, creating a contrast between the company’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4504":"桥水持仓","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0238689110.USD":"贝莱德环球动力股票基金","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BSX.AU":"BLACKSTONE MINERALS LTD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4581":"高盛持仓","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0122379950.USD":"贝莱德世界健康科学A2","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK7095":"多种金属与采矿","BSX":"波士顿科学","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","BK4213":"石油与天然气的勘探与生产","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","EP":"Empire Petroleum Corp"},"translate_title":"EP诉讼给FARAPULSE试验数据发布蒙上阴影后，波士顿科学公司(BSX)股价下跌5.8%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5,"EP":1.5,"BSX.AU":1.5},"content_text":"In late April 2026, Boston Scientific reported strong first-quarter results alongside reduced 2026 guidance, while unveiling extensive clinical data from Heart Rhythm 2026 supporting its FARAPULSE pulsed field ablation platform, WATCHMAN left atrial appendage closure devices, and EMBLEM MRI subcutaneous defibrillator. At the same time, multiple securities class actions were filed alleging misleading disclosures about electrophysiology growth, creating a contrast between the company’s clinical momentum and investors’ questions about prior communications. We’ll now examine how this mix of positive FARAPULSE trial outcomes and litigation over electrophysiology disclosures may reshape Boston Scientific’s investment narrative. The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementBoston Scientific Investment Narrative RecapTo own Boston Scientific, you need to believe that cardiology and electrophysiology innovation, especially FARAPULSE and WATCHMAN, can keep driving meaningful procedure adoption despite pricing, reimbursement and competition pressures. The key near term catalyst is how quickly physicians embrace pulsed field ablation in everyday practice, while the biggest current risk is that electrophysiology weakness and securities litigation around prior disclosures distract management and constrain investment; the latest Q1 beat does not erase those concerns. The Heart Rhythm 2026 data drop is particularly relevant here. AVANT GUARD and related FARAPULSE and WATCHMAN studies provided clinically strong, peer reviewed evidence in atrial fibrillation and stroke prevention, reinforcing the core product story that underpins many bullish models. At the same time, revised 2026 sales guidance and lawsuits over past electrophysiology growth commentary highlight that turning impressive trial results into durable, transparent commercial performance is not automatic. Yet beneath the positive trial headlines, investors should be aware that ongoing class actions over electrophysiology growth disclosures could... Read the full narrative on Boston Scientific (it's free!)Boston Scientific's narrative projects $26.9 billion revenue and $5.0 billion earnings by 2029.Uncover how Boston Scientific's forecasts yield a $95.75 fair value, a 69% upside to its current price.Exploring Other PerspectivesBSX 1-Year Stock Price Chart Some of the most optimistic analysts were assuming Boston Scientific could reach about US$28.0 billion in revenue and US$6.0 billion in earnings by 2029, but the latest EP litigation and guidance reset show how fragile those expectations can be if pulsed field ablation growth or WATCHMAN adoption ends up looking more like the more cautious scenario you have just read about.Explore 6 other fair value estimates on Boston Scientific - why the stock might be worth just $85.19!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Boston Scientific research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.Looking For Alternative Opportunities?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Boston Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632322779","isCrawlerRequest":true}